(PRWEB) March 10, 2013
Professor Virgil Stenberg, Ph.D., debunks the cortisone side effect myth and demonstrates effectiveness of a new cortisone use method.
Only two medicines have received the rare honor and prestige associated with the Nobel Prize: insulin and cortisone.
Medical industry has embraced insulin as a life-sustaining medicine for lifetime diabetes control.
On the other hand, medical industry has restricted cortisone to the minor role of resolving inflammation emergencies because of its side effects.
Stenberg, medical director of the Helen Foundation, noted that the medical industry restriction conflicts with elementary medical knowledge: hormones have no side effects, and cortisone is a hormone.
“To resolve the conflict, it became necessary to look beyond cortisone the medicine to cortisone the hormone,” Stenberg explained.
As a hormone, cortisone is in the blood at all times. There is a safe operating range of cortisone within the blood like there is a safe operating range of oil within an automobile engine. If this safe operating range is exceeded, Cushing’s syndrome appears. When the cortisone concentration is lower than the safe operating range, Addison’s disease threatens.
The relationship between arthritis inflammation and hormone cortisone within the body has been inadequately defined.
Normally, inflammation with its pain, swelling and redness is caused by an injury. The natural role of new inflammation is to prevent infection. After the danger of infection is passed, inflammation is terminated, and the injury heals.
Stenberg discovered inflammation is terminated by an on-demand, short-duration, huge cortisone pulse in the blood. As this pulse weakens, new inflammation lasts too long and evolves into old inflammation.
To bring his wife Helen’s severe, refractory arthritis under control, Stenberg designed replacement cortisone tablet use to timely restore the pulse to its working size. Using his design, Helen lost all pain and swelling in the first weeks and has remained as such for decades without cortisone side effects.
In a double-blind clinical trial on rheumatoid arthritis patients using the Stenberg treatment design (microdose therapy meaning a small amount of cortisone as needed), the results proved superior to standard treatments and with no significant side effects. Hamdy Kh Koryem of the University of Alexandra (Egypt) repeated the Stenberg double-blind clinical trial with near identical results. In a subsequent open, multi-clinic, study on 244 rheumatoid arthritis patients, the double-blind clinical trial results were again confirmed.
Stenberg adds, “Old inflammation has many names: rheumatoid arthritis when in the joints, bursitis in the bursa, myocytis in the muscles, pancreatitis in the pancreas, carditis in the heart, and so forth. One treatment that perfectly controls old inflammation should control all. Thus far, the Helen Foundation has applied microdose therapy to 26 diseases and disorders of inflammation for 1,890 patients all with superior results and no significant side effects.”
Stenberg states “By making the conclusion ‘cortisone has side effects’, a great error in medicine has been made. No other error in medicine has caused more pain and suffering. Cortisone ‘side effects’ are merely induced Cushing’s syndrome symptoms caused by over administration of cortisone. Over administration of cortisone was due to a lack of understanding of how the body normally uses cortisone to terminate inflammation.”
Dr. Stenberg is the author of “Arthritis: The Simple Solution” and “Fibromyalgia Solved” and has been: Editor of Proceedings of the North Dakota Academy of Sciences, President, North Dakota Academy of Sciences, President, Red River Valley Chapter, American Chemical Society, President of the Board, Listen and Drop In Center, for the mentally challenged, Board member, Interscience World Conference on Inflammation, Geneva, and Lecturer in Australia, Canada, France, India, Japan, Mexico, and Switzerland.
Dr. Stenberg has published medical articles on the cortisone pulse theory (Stenberg, V.I. et al. 1990. Negative endocrine control system for inflammation in rats. Agents Actions 29: 189-195) and superior efficacy on a demonstration disease of inflammation (Stenberg, V.I. et al. 1992. Endocrine control of inflammation: rheumatoid arthritis double-blind, crossover clinical trial. Int J Clin Pharmacol Res 12: 11-18).